Premarket Biotech Digest – $ACIU announces new discovery, $PMD launches new test, $NSPR receives NYSE notice

AC Immune SA ($ACIU) stock perked up as the company announced the discovery of two new antibodies using its proprietary SupraAntigen platform. These antibodies will be used against two targets in the pathogenesis of neurodegenerative diseases. The first is Alpha-synuclein, an established target for [...]

By |August 23rd, 2017|Digest|0 Comments

Premarket Biotech Digest – $WINT announces financial restructuring, $JNJ gets positive court verdict, $BIOC inks new deal

Ritter Pharmaceuticals ($RTTR) provided details about the Phase 3 program for lactose intolerance (LI) candidate RP-G28. The program incorporates guidance from the FDA during their End-of-Phase 2 meeting. The two studies to be conducted under this phase will both have the change in LI [...]

By |August 21st, 2017|Digest|0 Comments

Premarket Biotech Digest – $GMED receives clearance, $BIOC inks new collaboration, $PFE receives approval

Opko Health Inc. ($OPK) announced inking a commitment letter with Veterans Accountable Care Group, LLC. The collaboration is related to a Veterans Health Administration (VHA) contract. If the bid turns out to be successful then Opko will acquire a 15% stake in VACO. It [...]

By |August 18th, 2017|Digest|0 Comments

Premarket Biotech Digest – $COCP reports data, $SUPN gets favorable ruling, $FOLD receives approval

VBI Vaccines ($VBIV) announced that the FDA has approved its Investigational New Drug Application (IND) for immunotherapy candidate VBI-1901. The drug candidate is seeking approval as the potential treatment of Glioblastoma Multiforme (GBM), a common and aggressive type of malignant brain tumor. The IND [...]

By |August 16th, 2017|Digest|0 Comments

Premarket Biotech Digest – $SNGX receives funding, $ISRG board approves split, $SHPG receives Canadian approval

Achieve Life Sciences Inc. (NASDAQ:ACHV) stock perked up as the company announced received the FDA approval for its IND seeking approval to start U.S. clinical trials assessing smoking cessation drug cytosine. The company has already completed two large-scale Phase 3 studies, TASC and CASCAID, [...]

By |August 14th, 2017|Digest|0 Comments

Premarket Biotech Digest – $SGMO announces strong quarterly numbers, $APEN receives FDA alert, $CELG modifies collaboration

Sangamo Therapeutics ($SGMO) shot up as the company announced better than expected quarterly numbers. For the second quarter ended June 30, 2017, the company reported a consolidated net loss of $12.5 million, or $0.17 per share, compared to a net loss of $26.6 million, [...]

By |August 11th, 2017|Digest|0 Comments

Premarket Biotech Digest – $CLRB reports positive results, $TNDM receives new patent, $DERM inks new deal

Anthera Pharmaceuticals ($ANTH) stock shot up as the company announced that the FDA has designated its blisibimod an Orphan Drug for the treatment of immunoglobulin A nephropathy. The condition is also known as Berger's disease and is a disorder in which IgA builds up [...]

By |August 9th, 2017|Digest|0 Comments

Premarket Biotech Digest – $TEVA gets FDA approval, $IMMY under investigation, $FOLD reports quarterly numbers

Athersys ($ATHX) announced that the European Medicine Agency has decided that the design of its Phase 3 clinical trial, MASTERS-2, assessing its MultiStem cell therapy product in patients with ischemic stroke should be sufficient to support approval. The decision is in line with with [...]

By |August 7th, 2017|Digest|0 Comments

Premarket Biotech Digest – $LLY announces +ve results, $VTVT receives new patent, $ACRS files marketing application

Eli Lilly ($LLY) announced results from a second Phase 3 clinical trial assessing its lasmiditan for the acute treatment of migraine, which met its primary endpoint. The results were consistent with the first Phase 3, SAMURAI, reported about a year ago. At two hours [...]

By |August 4th, 2017|Digest|0 Comments

Premarket Biotech Digest – $VRTX gets FDA approval, $EYEG starts enrollment, $SGEN announces new deal

AstraZeneca ($AZN) reported receiving Breakthrough Therapy designation for its acalabrutinib for treating patients with mantle cell lymphoma who have received at least one prior line of therapy. The therapy is currently in a Phase 2 clinical trial. it is an orally available second generation [...]

By |August 2nd, 2017|Digest|0 Comments

Premarket Biotech Digest – $GILD receives EU approval, $IVC changes production site, $CYTR inks new deal

Dynavax Techologies ($DVAX) stock perked up as the company announced that an FDA advisory panel voted 12-1 in favor of the available data for is hepatitis B vaccine for adults. The advisory panel is of the view that the data supports the safety profile [...]

By |July 31st, 2017|Digest|0 Comments

Premarket Biotech Digest – $CERS inks new deal, $IDXG reports CIGNA coverage, $AZN announces negative results

Cerus Corporation ($CERS) stock perked up as the company announced inking deal with the Central California Blood Center. The new deal pertains to the company’s INTERCEPT plasma. The Center will use the plasma for manufacturing pathogen-reduced cryoprecipitate, to control bleeding in patients with acquired [...]

By |July 28th, 2017|Digest|0 Comments

Premarket Biotech Digest – $GALT receives new patent, $CYRX inks new deal, $CGNT announces acquisition,

Gelectin Therapeutics ($GALT) stock shot up as the company announced receiving a notice of allowance from the USPTO for a patent covering method of use of lead product candidate GR-MD-02 as a means to enhance anti-tumor activity and increase survival effects of combining GR-MD-02 [...]

By |July 26th, 2017|Digest|0 Comments

Premarket Biotech Digest – $BCLI receives new funding, $MNTA receives mixed ruling on litigation, $HCA inks new deal

Brainstorm Cell Therapeutics ($BCLI) announced that it has been awarded $16 million by the California Institute for Regenerative Medicine. The funds will be used for support the company’s pivotal Phase 3 clinical trial assessing NurOwn for the treatment of amyotrophic lateral sclerosis. The primary [...]

By |July 24th, 2017|Digest|0 Comments

Premarket Biotech Digest – $BVXV reports positive data, $AMGN receives FDA acceptance, $KANG inks new agreements

Diffusion Pharmaceutics ($DFFN) stock reacted positively to the news of the company achieving drug production milestone for its planned Phase 3 trial. The company completed a major production run of its lead drug candidate trans sodium crocetinate (TSC). The produced quantity is sufficient to [...]

By |July 21st, 2017|Digest|0 Comments

Premarket Biotech Digest – $TTOO gets CE Mark, $QURE receives new patent, $GILD receives FDA approval

Vertex Pharmaceuticals ($VRTX) reported positive mid-stage results from three different triple combination regimens in cystic fibrosis (CF) patients suffering from one F508del mutation and one minimal function mutation. The data from the Phase 2 study showed mean absolute improvements in lung function of 9.7% [...]

By |July 19th, 2017|Digest|0 Comments

Premarket Biotech Digest – $CTIC receives EMA validation, $AMGN seeks to add data, $EBS inks new deal

Biocept ($BIOC) stock showed strong movements as the company announced that its new liquid biopsy test for progesterone receptor (PR), a biomarker in the blood for breast cancer, is now commercially available. Veena Singh, M.D., Biocept's Senior Vice President and Medical Director said, “With [...]

By |July 17th, 2017|Digest|0 Comments

Premarket Biotech Digest – $FMI inks new deal, $SGMI gets Fast Track designation, $ANTM files a suit

Foundation Medicine Inc. (NASDAQ:FMI) announced inking a new deal with Kura Oncology for supporting enrollment in its its Phase 2 clinical trial evaluating farnesylation inhibitor tipifarnib in patients with treatment-resistant HRAS-mutant squamous cell carcinoma of the head and neck (SCCHN). Under the terms of [...]

By |July 14th, 2017|Digest|0 Comments

Premarket Biotech Digest – $SVRA reports positive interim results, $VBIV to start new studies, $KOOL inks a new agreement

Verastem Inc. ($VSTM) stock continues its upward trajectory as it gained further 16 percent in its previous trading session. The investors seem positive about the company’s prospects regarding its blood cancer candidate Duvelisib. The company recently reported long-term follow-up data from a Phase 2 [...]

By |July 12th, 2017|Digest|0 Comments

Premarket Biotech Digest – $PRAN announces new publication, $ALXN inks a new deal, $PRTA starts new study

Prana Biotechnology Limited ($PRAN) reported that its article “The novel compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease” was accepted for publication in the peer reviewed journal Acta Neuropathologica Communications. The company stock soared on the news. The [...]

By |July 6th, 2017|Digest|0 Comments
s2Member®